IsomAb Strengthens Its Leadership Team with Two New Key Appointments

IsomAb Strengthens Its Leadership Team with Two Key Appointments

In a significant expansion of its leadership team, IsomAb Ltd, a biotechnology company based in the UK, has announced the appointment of two highly experienced professionals. Dr. Shi Yin Foo has joined as a Non-Executive Director, while Dr. Gary Burgess has been appointed as Chief Medical Officer. These strategic hires are aimed at accelerating the progress of IsomAb's lead candidate, ISM-001, which targets peripheral arterial disease and other ischemic conditions.

The New Additions

Dr. Shi Yin Foo is not only the scientific founder and CEO of Arvada Therapeutics but also boasts an impressive academic and clinical background spanning more than two decades. Holding both an M.D. and a PhD in Immunology from Stanford University, as well as a Master's degree in Clinical Science from Harvard Medical School, she brings valuable insight and experience. Over the years, Dr. Foo has held executive roles in multiple biotechnology firms, including Novartis and Cardioxyl Pharmaceuticals. Her expertise lies in bringing innovative programs through the various stages of drug development, making her a key asset for IsomAb's future endeavors.

On the other hand, Dr. Gary Burgess joins IsomAb with over 20 years of extensive experience in all phases of drug development. His background includes senior positions at notable companies like Pfizer and Aerami Therapeutics, where he focused on regulatory aspects of drug development across various therapeutic areas. Dr. Burgess is particularly recognized for his expertise in conditions like Metabolic Associated Steatohepatitis (MASH) and pulmonary hypertension, adding depth to IsomAb’s medical leadership.

Perspectives from Leadership

Jackie Turnbull, CEO of IsomAb, expressed excitement regarding the new appointments, emphasizing that Dr. Foo and Dr. Burgess will greatly enhance the company's existing capabilities. Turnbull stated, "IsomAb's lead antibody targeting VEGF-A165b aims to treat peripheral arterial disease in a significant proportion of patients suffering from concurrent metabolic syndrome or Type II diabetes. With ISM-001 preclinical work progressing swiftly, we are delighted to fortify our team with the cardiovascular therapeutic development experience of both Dr. Foo and Dr. Burgess."

The leadership transitions come at a critical time as IsomAb focuses on advancing its innovative solutions for serious health conditions. ISM-001, the company’s flagship product, is designed to restore blood flow in ischemic tissues, which could significantly impact patients' quality of life.

About IsomAb Ltd

Founded in 2022 as a spin-off from the University of Nottingham, IsomAb Ltd specializes in the development of isoform-specific disease-modifying antibody treatments. The company is built upon pioneering research into VEGF-A and its splice isoforms, and aims to tackle life-threatening diseases such as peripheral arterial disease. Early investigations conducted at the University of Bristol have also contributed to IsomAb's foundational knowledge and capabilities.

Supported by substantial funding from reputable organizations such as the British Heart Foundation, the Wellcome Trust, and the Medical Research Council, IsomAb is positioned for impactful innovations in the biopharmaceutical field. Its lead product, ISM-001, signifies hope for many patients suffering from ischemic diseases.

Conclusion

The appointments of Dr. Shi Yin Foo and Dr. Gary Burgess mark an exciting chapter for IsomAb as it looks to enhance its therapeutic offerings and expedite the therapeutic development process. With these seasoned professionals on board, the company is poised to make significant strides in treating peripheral arterial disease and improving patient outcomes. As IsomAb continues to evolve, stakeholders and patients alike will be watching closely to see how these strategic decisions will influence their innovative drug development journey.